Sunshine Biopharma
SBFM
2 hedge funds and large institutions have $415K invested in Sunshine Biopharma in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
6.3% less ownership
Funds ownership: 11.38% → 5.08% (-6.3%)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $537K
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
-$537K |
SBFM Hedge Fund Activity: Q3 2023 in Review
2 of the 6,318 institutional investors tracked by Wall St. Rank reported a position in Sunshine Biopharma (SBFM) for Q3 2023, worth a combined $415K — down 67% from $1.25M a quarter earlier.
Fund positioning in SBFM was balanced in Q3 2023: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was Armistice Capital, cutting an estimated $537K.
- 2 institutional investors held Sunshine Biopharma (SBFM) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $415K of Sunshine Biopharma stock for Q3 2023, down 67% quarter-over-quarter.
- 0 funds opened new Sunshine Biopharma positions in Q3 2023 and 0 closed out.
- The largest Sunshine Biopharma seller in Q3 2023 was Armistice Capital, an estimated $537K sold.
Based on aggregated 13F filings for Q3 2023.